First group of healthy volunteers dosed in company’s phase I trial of novel non-hallucinogenic psychoplastogen with no psychotomimetic effects BOSTON, June 20, 2023 /PRNewswire/ — Delix Therapeutics (the “Company”), a clinical-stage neuroscience company developing novel neuroplasticity-promoting therapeutics for psychiatric and neurological conditions, today announced the completion of dosing of…
